COVID-19 Impact on Global Non-small Cell Lung Cancer Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Biologics
  • 1.4.3 Small Molecule Targeted Therapy
  • 1.4.4 Chemotherapy
  • 1.4.5 Other
• 1.5 Market by Application
  • 1.5.1 Global Non-small Cell Lung Cancer Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Lung Adenocarcinoma
  • 1.5.3 Squamous Cell Lung Carcinoma
  • 1.5.4 Large-cell Lung Carcinoma
• 1.6 Coronavirus Disease 2019 (Covid-19): Non-small Cell Lung Cancer Drugs Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Non-small Cell Lung Cancer Drugs Industry
    • 1.6.1.1 Non-small Cell Lung Cancer Drugs Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Non-small Cell Lung Cancer Drugs Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Non-small Cell Lung Cancer Drugs Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Non-small Cell Lung Cancer Drugs Market Perspective (2015-2026)
• 2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Regions
  • 2.2.1 Non-small Cell Lung Cancer Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Non-small Cell Lung Cancer Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Non-small Cell Lung Cancer Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Non-small Cell Lung Cancer Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Non-small Cell Lung Cancer Drugs Players by Market Size
  • 3.1.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio
  • 3.2.1 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Drugs Revenue in 2019
• 3.3 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served
• 3.4 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
• 3.5 Date of Enter into Non-small Cell Lung Cancer Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2021-2026)

5 Non-small Cell Lung Cancer Drugs Breakdown Data by Application (2015-2026)

• 5.1 Global Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)
• 5.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 6.2 Non-small Cell Lung Cancer Drugs Key Players in North America (2019-2020)
• 6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 6.4 North America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 7.2 Non-small Cell Lung Cancer Drugs Key Players in Europe (2019-2020)
• 7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 7.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 8.2 Non-small Cell Lung Cancer Drugs Key Players in China (2019-2020)
• 8.3 China Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 8.4 China Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 9.2 Non-small Cell Lung Cancer Drugs Key Players in Japan (2019-2020)
• 9.3 Japan Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 9.4 Japan Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 10.2 Non-small Cell Lung Cancer Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 11.2 Non-small Cell Lung Cancer Drugs Key Players in India (2019-2020)
• 11.3 India Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 11.4 India Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
• 12.2 Non-small Cell Lung Cancer Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AstraZeneca
  • 13.1.1 AstraZeneca Company Details
  • 13.1.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Introduction
  • 13.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020))
  • 13.1.5 AstraZeneca Recent Development
• 13.2 Bristol-Myers Squibb Company
  • 13.2.1 Bristol-Myers Squibb Company Company Details
  • 13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
  • 13.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Introduction
  • 13.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
  • 13.2.5 Bristol-Myers Squibb Company Recent Development
• 13.3 Eli Lilly and Company
  • 13.3.1 Eli Lilly and Company Company Details
  • 13.3.2 Eli Lilly and Company Business Overview and Its Total Revenue
  • 13.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Introduction
  • 13.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
  • 13.3.5 Eli Lilly and Company Recent Development
• 13.4 F. Hoffmann-La Roche Ltd
  • 13.4.1 F. Hoffmann-La Roche Ltd Company Details
  • 13.4.2 F. Hoffmann-La Roche Ltd Business Overview and Its Total Revenue
  • 13.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Introduction
  • 13.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
  • 13.4.5 F. Hoffmann-La Roche Ltd Recent Development
• 13.5 Merck & Co., Inc.
  • 13.5.1 Merck & Co., Inc. Company Details
  • 13.5.2 Merck & Co., Inc. Business Overview and Its Total Revenue
  • 13.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Introduction
  • 13.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
  • 13.5.5 Merck & Co., Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer